Lindt holds back on Canada supply shift, boosts local stocks
The company said in March it would supply chocolate made in Europe to Canada to avoid tariffs imposed to counter higher U.S. customs duties.
But since March, there have been several changes to tariffs placed on imports and exports from the United States, prompting many companies to adopt a wait-and-see approach to the changing trading conditions.
"We have not adjusted any sourcing strategy as the situation develops so fast," a Lindt spokesperson told Reuters in an email on Tuesday. "As soon as we have a clearer and more stable overview of the situation, we decide if and how to adjust our sourcing strategy."
The spokesperson said that shifting sourcing of products sold in Canada to Europe was "one option that is being discussed", but the company has not yet decided how to proceed.
"This was one of the options that was considered and can be implemented if necessary," the spokesperson said.
Lindt said it had temporarily increased stock levels in Canada as a safeguard against potential supply disruptions in light of the imposed counter-tariffs on products imported from the United States.
In March, Lindt said that 50% of its Canadian chocolate supply originated from the United States, but those volumes could be entirely shifted to Europe.
Lindt produces 95% of its U.S. market chocolates in its five domestic factories, which also serve Canada.
This month, Swiss chocolate maker Barry Callebaut's (BARN.S), opens new tab chief executive said it was planning to increase its U.S.-based production to fend off effects of the "disruptive environment" in North America.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
3 minutes ago
- Reuters
Exclusive: US pharma tariffs likely weeks away as Trump plans for Alaska, sources say
WASHINGTON Aug 13 (Reuters) - The announcement by President Donald Trump's administration of the results of a probe into pharmaceutical imports and new sector-specific U.S. tariffs likely remains weeks away, four official and industry sources said, later than initially promised as he focuses on other matters. Commerce Secretary Howard Lutnick had said in April when the review of whether reliance on foreign drug production threatens U.S. national security was launched that he anticipated that it would conclude between mid-May and mid-June. Global pharmaceutical companies are bracing for the outcome of the investigation, which will usher in sector-specific tariffs that Trump has said could start small and eventually rise to 250%. The Republican president said as recently as last week that his plan relies on phased-in tariffs, giving drugmakers time to increase manufacturing in the United States as he pushes to alter what he says are global trade distortions in many industries. One government official in Europe and a source with knowledge of the White House process, as well as two sources at European drug firms familiar with the process, told Reuters that the report and tariffs announcement was not imminent and likely weeks away. These sources spoke on condition of anonymity. A White House spokesperson, asked about media reporting indicating that the results of the probe could be several weeks away, cautioned that such reports were pure speculation unless confirmed by the White House. The spokesperson declined to give further details about the timing of the pharma probe or one involving semiconductors. The investigation is examining pharmaceutical imports ranging from finished prescription drugs to active pharmaceutical ingredients, called APIs, and other raw materials, with the results to be disclosed in a Commerce Department report. Lutnick said last month the tariff plan that will be based on the report would be completed by the end of July. Lutnick then said on July 29 it would be two more weeks. The investigation was launched under Section 232 of the Trade Expansion Act of 1962. While the investigation is ongoing, the pharmaceutical sector has been exempted from the sweeping tariffs imposed by the Trump administration. The United States has reached bilateral trade deals with the UK, Japan, South Korea and the European Union that promised more favorable terms for their pharma exports than those expected to be levied on the sector globally. A European government official said that an announcement before the end of August appears unlikely but cautioned that the timeline could shift depending on other developments. A source at a European drugmaker said the Trump administration is focused on the U.S.-Russia summit in Alaska on Friday and therefore no announcement is expected this week. The source familiar with the White House process said that announcement is unlikely to come this week given other priorities. That source and one other source said that they expect the Trump administration to announce the results of its national security investigation into semiconductors first, followed by the pharma announcement, putting it a few weeks away. The Section 232 provision authorizes the president to adjust imports - including imposing tariffs - if a category of goods is being imported into the United States in quantities that "threaten or impair the national security." Medical goods historically have been spared from trade wars due to the potential harm to patient access, and drugmakers have said tariffs could undercut other health policy goals outlined by the Trump administration, including lowering drug prices. U.S. tariffs on imported pharmaceutical products would mark the latest in a series of sectoral tariffs announced by the administration, following metals and cars, that some economists have predicted will drive up costs for American consumers.
Reuters
an hour ago
- Reuters
Canada's Gildan to buy Hanesbrands for $2.2 billion to expand basic apparel business
Aug 13 (Reuters) - Gildan Activewear ( opens new tab has agreed to buy U.S. undergarments maker Hanesbrands (HBI.N), opens new tab for $2.2 billion in cash and stock, the companies said on Wednesday, as the Canadian firm looks to expand its foothold in basic apparel. Gildan, whose brands include Anvil, Gildan and Gold Toe, will pay about $6 per Hanesbrands share, representing a 24% premium to Monday's close and implying an equity value of $2.2 billion. Shares of Hanesbrands rose 2.6% at $6.34 in early trading after surging as much as 40% a day earlier, when news of the buyout first emerged. The deal combines Hanesbrands' branded retail foothold through its popular brands such as Hanes, Bonds, Maidenform and Playtex with Gildan's strong wholesale market presence across the United States, Canada, Latin America, Asia-Pacific and Europe. "The combination of these two large manufacturers... makes sense on paper," Citigroup analysts said after news of the takeover, adding that Gildan could manage Hanesbrands' business more efficiently, given its expertise in low-cost manufacturing. The Financial Times first reported on the potential deal on Tuesday, followed by other media outlets including Reuters. The deal caps a turbulent chapter for Hanesbrands that was marked by years of underinvestment, heavy debt and a string of acquisitions that produced mixed results since its spinoff from conglomerate Sara Lee in 2006. Hanesbrands' sales have plunged over the last three years amid stiff competition in the athleisure market and cooling demand, but cost-reduction efforts and supply-chain improvements lifted its margins in the past year. In a move to focus on its core categories, Hanesbrands has steadily offloaded assets, including selling its sportswear brand Champion to Authentic Brands in a $1.2 billion deal last year. Gildan said it intends to initiate a review of strategic alternatives for Hanesbrands Australia, which could include a sale or other transaction, after the deal closes. The transaction is expected to close in late 2025 or early 2026 and is likely to be immediately accretive to adjusted profit per share.
Daily Mail
an hour ago
- Daily Mail
Insider shares insights on Trump's diplomatic tactics
As crunch talks were underway between the United States and China in Donald Trump 's first term, Xi Jinping 's negotiating team used every trick in the book to unsettle the American side. Shortly before a key meeting took place, as the U.S. team was about to set out from their embassy in Beijing , the Chinese delivered a follow-up to a carefully prepared negotiating document for the talks. It was in Chinese, without an English translation. Then, when Trump's negotiating team got to the Diaoyutai State Guesthouse for the meeting, they discovered there were one too few chairs for them. One of the U.S. negotiators had to leave the room. 'We're sitting in a secure facility, a team of tens of people that have come over from the U.S., and we looked at the document they provided. It was in Chinese, it was not at all responsive to the draft we sent before travelling to Beijing,' Mitchell Silk, former Assistant Secretary of the Treasury, told the Daily Mail. Silk shared his insights on Trump's diplomatic tactics ahead of the president's historic showdown with Vladimir Putin in Alaska on Friday. 'They completely disregarded our document. They delivered up something that they wanted to use for the negotiations,' Silk said of the Chinese ahead of the 2019 summit with Trump. In his upcoming book 'A Seat at the Table,' Silk, who speaks two dialects of Chinese, recounts how he quickly translated the document in the car en route to the talks with Secretary of the Treasury Steven Mnuchin. When they got there Mnuchin made it clear the Americans weren't meeting for the sake of it. 'He was just very short and very simple, he was perfectly gracious in, thanking the Vice Premier for his kind and warm welcome. He acknowledged receipt of the document, and he just took our document, waved it around, and said, thank you but I think we're going to be using our document for these discussions, and that's exactly what we did,' said Silk. 'There was no funny business. There were no games. We were there to do business, and we weren't having any of it.' He added :'If it had been another administration, another time, and this is probably what was happening in these endless, meaningless meetings prior to Trump, somebody would have said, well, you know, maybe we should we use their document? There was none of that. Psychologically, we weren't having it, and we made that very clear.' During the talks, which led to Trump's first trade deal with China in 2020, every little detail of protocol had been worked out over preceding weeks, including who was going to sit where. But when everybody sat down, right before the then Chinese Vice Premier Liu He spoke, it was clear that there was one chair missing. Someone on the American side had to leave the room, and one of the dedicated career civil servants took the fall. Later, outside of the main room, Silk engaged with the head of protocol from the Ministry of Foreign Affairs. It emerged that the Chinese felt snubbed because the Vice Premier had not been granted an Oval Office audience when he was in Washington just weeks prior. 'Our understanding was the chair was their way of getting back at us, rather petty,' said Silk. Ultimately, the head of the Chinese central bank, Yi Gang, was walking by and Silk told him: 'Mr. Governor, when you are next in Washington, please join me at my house for a dinner. I will put out a lavish spread for you with the finest of drink and the finest of food, and you can have as many chairs as you like.' The American team got their chair back. It was yet another example of the psychological games that Trump will face in his upcoming tariff negotiations with the Chinese. This week, President Trump extended a trade truce with China for another 90 days, delaying a dangerous showdown between the world's two biggest economies. The previous deadline was set to expire at 12:01am on Tuesday. Had that happened the U.S. could have ratcheted up taxes on Chinese imports from an already high 30 percent, and Beijing could have responded by raising retaliatory levies on U.S. exports to China. Key has been the use of executive power to deploy tariffs as leverage. 'He's come out swinging, using tariffs imposed under executive order, so presidential authority, as an economic weapon, and he started that literally in the first days of the administration,' said Silk. 'The heavy and the quick action certainly rattled the markets, but I believe that the president was playing for long-term economic leverage.' The tariffs have been 'much sharper, they're more targeted, and they're higher than before.' Behind that was a strategy to 'clear the decks' of other trading partners, securing quick deals with them, so that he could focus on China. 'My take is that the initial move was designed to get initial action out of a certain set of countries (including the UK, EU, Japan and South Korea), and push a second group of countries further down the road, try to pick them off one by one.' He added: 'And then you've got the most difficult countries, and the number one, without a close second in that group, is China.' Realistically, the China negotiation is probably a 12-to-18 month process, he said.
